Translating genome-wide association findings into new therapeutics for psychiatry

Nat Neurosci. 2016 Oct 26;19(11):1392-1396. doi: 10.1038/nn.4411.


Genome-wide association studies (GWAS) in psychiatry, once they reach sufficient sample size and power, have been enormously successful. The Psychiatric Genomics Consortium (PGC) aims for mega-analyses with sample sizes that will grow to >1 million individuals in the next 5 years. This should lead to hundreds of new findings for common genetic variants across nine psychiatric disorders studied by the PGC. The new targets discovered by GWAS have the potential to restart largely stalled psychiatric drug development pipelines, and the translation of GWAS findings into the clinic is a key aim of the recently funded phase 3 of the PGC. This is not without considerable technical challenges. These approaches complement the other main aim of GWAS studies, risk prediction approaches for improving detection, differential diagnosis, and clinical trial design. This paper outlines the motivations, technical and analytical issues, and the plans for translating PGC phase 3 findings into new therapeutics.

Publication types

  • Review

MeSH terms

  • Animals
  • Genetic Predisposition to Disease*
  • Genome-Wide Association Study*
  • Humans
  • Mental Disorders / genetics*
  • Polymorphism, Single Nucleotide / genetics*
  • Psychiatry*
  • Risk Assessment